Clinical Trial Update: Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating NY-ESO-1 protein with CpG 7909 in prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CPG 7909 (CpG 7909)
• NY-ESO-1 protein (NY-ESO-1 recombinant protein)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Prostate Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-01-27